Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.…
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Celldex Therapeutics (NASDAQ: CLDX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 198 employees.
The shares were at 27.42 USD on 20 November 2026, up 19.7% over 52 weeks. Its 52-week range is 22.10 USD to 45.14 USD: the price is 39.3% below the high and 24.1% above the low.
Its market capitalisation is 2.15B USD.
Celldex Therapeutics reports return on equity of -49.1%.
It holds more cash than debt, a net cash position of 640.45M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 61.57 USD is 124.5% above the current price. The next earnings report is expected on 25 February 2027.